Unlike other medical treatments for which companies are driven to keep their products safe because of liability threats, their brief says «the
Vaccine Program itself provides no incentive to vaccine manufacturers to make their vaccines safer.
Vaccine Program itself
provides no incentive to
vaccine manufacturers to make their vaccines safer.
vaccine manufacturers to make their
vaccines safer.»
Nearly 80 million people in 77 countries received the influenza
vaccine with WHO's help — including
providing a «seed» strain of the virus used by
manufacturers — but the report says that «numerous systemic difficulties» slowed distribution to low - resource countries.
Moving the Needle
provides quarterly updates from PATH's Center for
Vaccine Innovation and Access (CVIA) on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine techno
Vaccine Innovation and Access (CVIA) on our
vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine techno
vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing - country
vaccine manufacturers, and evaluating new adjuvants and other novel vaccine techno
vaccine manufacturers, and evaluating new adjuvants and other novel
vaccine techno
vaccine technologies.